|
ATCC
a549 lung cancer cell a (IC 50 (µM A549 Lung Cancer Cell, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/a549 lung cancer cell/product/ATCC Average 99 stars, based on 1 article reviews
a549 lung cancer cell - by Bioz Stars,
2026-03
99/100 stars
|
Buy from Supplier |
|
AMS Biotechnology
late stage tumor tissue a (IC 50 (µM Late Stage Tumor Tissue, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/late stage tumor tissue/product/AMS Biotechnology Average 96 stars, based on 1 article reviews
late stage tumor tissue - by Bioz Stars,
2026-03
96/100 stars
|
Buy from Supplier |
|
Hmong National Development
gastric cancer a (IC 50 (µM Gastric Cancer, supplied by Hmong National Development, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/gastric cancer/product/Hmong National Development Average 90 stars, based on 1 article reviews
gastric cancer - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Nanotherapeutics
sirna nanotherapy a (IC 50 (µM Sirna Nanotherapy, supplied by Nanotherapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sirna nanotherapy/product/Nanotherapeutics Average 90 stars, based on 1 article reviews
sirna nanotherapy - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
ATCC
pc3 ![]() Pc3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/pc3/product/ATCC Average 99 stars, based on 1 article reviews
pc3 - by Bioz Stars,
2026-03
99/100 stars
|
Buy from Supplier |
|
CH Instruments
chi-square test ![]() Chi Square Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/chi-square test/product/CH Instruments Average 90 stars, based on 1 article reviews
chi-square test - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
ATCC
late stage metastatic prostate cancer cells ![]() Late Stage Metastatic Prostate Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/late stage metastatic prostate cancer cells/product/ATCC Average 99 stars, based on 1 article reviews
late stage metastatic prostate cancer cells - by Bioz Stars,
2026-03
99/100 stars
|
Buy from Supplier |
|
China Pharmaceuticals Inc
late-stage metastatic breast cancer ![]() Late Stage Metastatic Breast Cancer, supplied by China Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/late-stage metastatic breast cancer/product/China Pharmaceuticals Inc Average 90 stars, based on 1 article reviews
late-stage metastatic breast cancer - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Pfizer Inc
products for treatment of early and late stage breast cancer ![]() Products For Treatment Of Early And Late Stage Breast Cancer, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/products for treatment of early and late stage breast cancer/product/Pfizer Inc Average 90 stars, based on 1 article reviews
products for treatment of early and late stage breast cancer - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
ATCC
dld 1 ![]() Dld 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/dld 1/product/ATCC Average 99 stars, based on 1 article reviews
dld 1 - by Bioz Stars,
2026-03
99/100 stars
|
Buy from Supplier |
|
GraphPad Software Inc
graphpad prism software ![]() Graphpad Prism Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/graphpad prism software/product/GraphPad Software Inc Average 90 stars, based on 1 article reviews
graphpad prism software - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Jackson Laboratory
irfp + /luc + 4t1 cells ![]() Irfp + /Luc + 4t1 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/irfp + /luc + 4t1 cells/product/Jackson Laboratory Average 90 stars, based on 1 article reviews
irfp + /luc + 4t1 cells - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
Image Search Results
a (IC 50 (µM Journal: Journal of Enzyme Inhibition and Medicinal Chemistry
Article Title: Synthesis and characterisation of ( Z )-styrylbenzene derivatives as potential selective anticancer agents
doi: 10.1080/14756366.2018.1513925
Figure Lengend Snippet: In vitro anti-proliferative activity of the synthesised compounds, CA-4, CA-4P, and taxol against eleven cell lines
Article Snippet: MGC-803 late-stage differentiation gastric cancer cell,
Techniques: In Vitro, Activity Assay
Journal: Journal of Enzyme Inhibition and Medicinal Chemistry
Article Title: Synthesis and characterisation of ( Z )-styrylbenzene derivatives as potential selective anticancer agents
doi: 10.1080/14756366.2018.1513925
Figure Lengend Snippet: Selectivity index values of compounds relative to the effects on normal cell L-02 or MCF-10A cells.
Article Snippet: MGC-803 late-stage differentiation gastric cancer cell,
Techniques:
Journal: bioRxiv
Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy
doi: 10.1101/2023.09.18.558190
Figure Lengend Snippet: DHRS7 expression, subcellular localization, and orientation. (A) Plotted as x-fold over the median value across 84 human tissues, expression data extracted from BioGPS reveals DHRS7 to be highly preferentially expressed in normal prostate (14 extracted tissues shown). (B) Levels of DHRS7 protein in LNCaP and PC3 cells determined by Western blot. Numbers on the left indicate molecular weights. (C) Antibody staining for DHRS7 in LNCaP cells reveals a strong nuclear envelope accumulation along with diffuse staining in the ER. Notably, levels are very low in the bottom cell indicating expression variability in the population. Scale bar, 10 µm. (D) A model for DHRS7 transmembrane helices was generated using TMHMM v2.0. (E) Determination of topology using the digitonin assay. Cells expressing a DHRS7-mRFP fusion were permeabilized with either Triton X-100 which removes all membranes or digitonin which preferentially pokes holes in the plasma membrane where cholesterol is abundant. Cells were then fixed and stained with an antibody against mRFP. If the epitope is in the lumen it is masked and so will be inaccessible to the antibody so that there would be less signal from the antibody than from the mRFP. The similar staining pattern indicates the epitope on the C-terminal region of the protein is accessible to the cytoplasm/ nucleoplasm. Scale bar 10 μm.
Article Snippet:
Techniques: Expressing, Western Blot, Staining, Generated, Clinical Proteomics, Membrane
Journal: bioRxiv
Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy
doi: 10.1101/2023.09.18.558190
Figure Lengend Snippet: DHRS7 can direct nuclear size changes in prostate cancer cells. (A) Protein levels of DHRS7 by Western before and after siRNA knockdown (25 nM) in LNCaP cells. Numbers on the left indicate molecular weights. (B) Whisker-scatterplot chart showing quantification of volume reconstructions for ∼100 LNCaP cells knocked down for DHRS7 shows its loss resulted in increased nuclear size. (C) Whisker-scatterplot chart showing the quantification of volume reconstructions for ∼100 PC3 and HT1080 cells with or without exogeneous DHRS7 expression as indicated. Exogenous expression of DHRS7 in late-stage PCa PC3 cells yields decreased nuclear size. All statistical analyses were performed with unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
Article Snippet:
Techniques: Western Blot, Knockdown, Whisker Assay, Expressing
Journal: bioRxiv
Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy
doi: 10.1101/2023.09.18.558190
Figure Lengend Snippet: Medium-throughput screen for compounds decreasing nuclear size in PC3 cells. (A) Screening approach. Drug-treated PC3 cells stably expressing H2B-RFP to determine nuclear size were stained after fixation with CellMask Deep Red dye to determine the total cell area. (B) Replicate screens of plate 6 from the Microsource Spectrum library (compounds listed on Table 1, concentration: 10 μM). Nuclear size (vertical axis) was averaged over a total of 350-4,000 cells per well (horizontal axis). A1/A12, B1/B12 … G1/G12: DMSO controls. Estradiol propionate (EP) is indicated (red circles). Nuclear size reduction by at least 20% was statistically significant (p<0.001, Wilcoxson rank test). (C) Molecular structures of estradiol (top) and EP (bottom). (D) Characteristic images of EP (left) and estradiol benzoate (right)-treated cells (blue: H2B-RFP nuclear signal; red: CellMask Deep Red cytosolic signal).
Article Snippet:
Techniques: Stable Transfection, Expressing, Staining, Concentration Assay
Journal: bioRxiv
Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy
doi: 10.1101/2023.09.18.558190
Figure Lengend Snippet: Estradiol propionate only corrects the cancer nuclear size defect in the absence of DHRS7. (A-D) Whisker-scatterplot charts showing the quantification of nuclear volume in ∼100 cells in presence of the indicated concentrations of estradiol propionate (EP). (A) Wild-type LNCaP cells. (B) LNCaP cells with siRNA-mediated DHRS7 knockdown. (C) Wild-type PC3 cells. (D) PC3 cells with exogenously restored DHRS7 expression. All statistical analyses were performed with unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
Article Snippet:
Techniques: Whisker Assay, Knockdown, Expressing
Journal: bioRxiv
Article Title: Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy
doi: 10.1101/2023.09.18.558190
Figure Lengend Snippet: DHRS7 dehydrogenase activity is likely required for its effects on nuclear size. (A) Sequence alignment of DHRS7 against 11β-HDS-B1 and 17-β-HDS-1. The mutated arginine (R82 in DHRS7) is highlighted in blue while residues conserved are in green and conservation of amino acid functionality is indicated in yellow. (B) Structural prediction for DHRS7 generated with the Phyre2 web server, www.sbg.bio.ic.ac.uk/phyre2 /, using human 11β-HDSB1 - PDB 2ILT 1BHS. (C-D) Whisker-scatterplot charts showing the quantification of nuclear volume in ∽100 PC3 cells expressing DHRS7 either wild-type or R82E (C) or PC3 cells expressing DHRS7 R82E mutant in presence of the indicated concentrations of estradiol propionate (EP) (D). All statistical analyses were performed using unpaired t-test with Welch’s correction: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
Article Snippet:
Techniques: Activity Assay, Sequencing, Structural Proteomics, Generated, Whisker Assay, Expressing, Mutagenesis
Journal: Molecular imaging and biology
Article Title: Nanoparticle Formulation of Indocyanine Green Improves Image-Guided Surgery in a Murine Model of Breast Cancer
doi: 10.1007/s11307-019-01462-y
Figure Lengend Snippet: Identification of small, occult lesions with FIGS. Color and 800 nm images were obtained during FIGS with the Lab-FLARE RP1 FIGSS. Resected tissues were imaged with the Pearl Trilogy Small Animal Imaging System to confirm presence of tumor with iRFP and 800 nm fluorescence. a,b Red boxes and arrows indicate tissues resected with NanoICG guidance. c Imaging was analyzed with Image Studio software with which tumor areas were calculated. H&E-stained sections of resected tissues were analyzed by a board-certified pathologist. Primary tumor from d the NanoICG group was recognized as tumor (main image: 400×, scale bar = 20 μm; inset image: 40×, scale bar = 200 μm; green arrow indicates area of 400× image). Representative examples of e small, occult lesions that were classified as “tumor-positive” (main image: 400×, scale bar = 20 μm; inset image: 100×, scale bar = 100 μm; green arrow indicates area of 400× image) or f “tumor-negative” (100×, scale bar = 100 μm). Color bar values are reported in AU.
Article Snippet: Tumor models were established by implanting 2.5 × 10 4 (early-stage breast tumor study) or 2.0 × 10 5 (
Techniques: Imaging, Fluorescence, Software, Staining